Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 752Pancreatic Neoplasms 665Stomach Neoplasms 387Carcinoma, Non-Small-Cell Lung 376Carcinoma, Hepatocellular 368Breast Neoplasms 316Colonic Neoplasms 279Ovarian Neoplasms 260Neoplasms 250Esophageal Neoplasms 237Neoplasm Metastasis 215Rectal Neoplasms 202Melanoma 195Lung Neoplasms 193Liver Neoplasms 180Squamous Cell Carcinoma of Head and Neck 150Carcinoma, Renal Cell 146Head and Neck Neoplasms 124Prostatic Neoplasms 123Triple Negative Breast Neoplasms 110Uterine Cervical Neoplasms 106Urinary Bladder Neoplasms 106Cholangiocarcinoma 104Endometrial Neoplasms 101Sarcoma 100Small Cell Lung Carcinoma 74Gastrointestinal Neoplasms 73Esophageal Squamous Cell Carcinoma 68Kidney Neoplasms 63Carcinoma, Transitional Cell 60

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Non functioning pancreatic endocrine tumor × Gastrointestinal × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡